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ABSTRACT
This work is motivated by the need of providing patients with a decision support system
that facilitates the selection of the most appropriate treatment strategy in cancer treatment.
Treatment options are currently subject to predetermined clinical pathways and medical
expertise, but generally, do not consider the individual patient characteristics or preferences.
Although genomic patient data are available, this information is rarely used in the clinical setting
for real-life patient care. In the area of personalized medicine, the advancement in the
fundamental understanding of cancer biology and clinical oncology can promote the prevention,
detection, and treatment of cancer diseases.
The objectives of this research are twofold. 1) To develop a patient-centered decision
support model that can determine the most appropriate cancer treatment strategy based on
subjective medical decision criteria, and patient’s characteristics concerning the treatment
options available and desired clinical outcomes; and 2) to develop a methodology to organize
and analyze gene expression data and validate its accuracy as a predictive model for patient’s
response to radiation therapy (tumor radiosensitivity).
The complexity and dimensionality of the data generated from gene expression
microarrays requires advanced computational approaches. The microarray gene expression data
processing and prediction model is built in four steps: response variable transformation to
emphasize the lower and upper extremes (related to Radiosensitive and Radioresistant cell
lines); dimensionality reduction to select candidate gene expression probesets; model
development using a Random Forest algorithm; and validation of the model in two clinical
cohorts for colorectal and esophagus cancer patients.
vi

Subjective human decision-making plays a significant role in defining the treatment
strategy. Thus, the decision model developed in this research uses language and mechanisms
suitable for human interpretation and understanding through fuzzy sets and degree of
membership. This treatment selection strategy is modeled using a fuzzy logic framework to
account for the subjectivity associated to the medical strategy and the patient’s characteristics
and preferences. The decision model considers criteria associated to survival rate, adverse
events and efficacy (measured by radiosensitivity) for treatment recommendation. Finally, a
sensitive analysis evaluates the impact of introducing radiosensitivity in the decision-making
process.
The intellectual merit of this research stems from the fact that it advances the science of
decision-making by integrating concepts from the fields of artificial intelligence, medicine,
biology and biostatistics to develop a decision aid approach that considers conflictive objectives
and has a high practical value. The model focuses on criteria relevant to cancer treatment
selection but it can be modified and extended to other scenarios beyond the healthcare
environment.

vii

CHAPTER 1: INTRODUCTION
1.1 Background
Rectal cancer is a disease in which malignant cells form in the tissues of the rectum [1].
The rectum is part of the colon and is located in the gastrointestinal track; thus, its position in
the pelvis poses additional challenges in treatment when compared with colon cancer (see
Figure 1) [2].

Figure 1 Diagram of colon and rectum. National Cancer Institute ©2013 Terese
Winslow
Colorectal cancer is the third most common cancer diagnosed in both men and women
in the United States. According to the American Cancer Society, 96,830 new cases of colon
cancer and 40,000 new cases of rectal cancer were reported in 2014 [2]. However, rates have
been declining by 3% per year in men and by 2.3% per year in women since 1998. This trend
has been attributed to the detection and removal of precancerous polyps as a result of
1

colorectal cancer screening [3] . Overall, only 39% of colorectal cancer patients diagnosed
between 1999 and 2006 had localized-stage disease, for which the 5-year relative survival rate
is 90%; 5-year survival rates for patients diagnosed at the regional and distant stage are 70%
and 12%, respectively [4]. The 5-year observed survival rate for colon and rectal cancer
patients between 1998 and 2000 are shown in Table 1 by cancer staged from the 7th edition of
the AJCC staging system (from National Cancer Institute's SEER database) [5]. The observed
estimates in Table 1 may be lower than actual survival rates since it includes patients who could
have died from other causes than cancer during the observed timeframe (e.g. heart disease).
Table 1 Survival rates for rectal and colon cancer by stage
5-year Observed Survival Rate
Stage

Colon Cancer (%)

Rectal Cancer (%)

II

74

74

IIA

67

65

IIB

59

52

IIC

37

32

IIIA

73

74

IIIB

46

45

IIIC

28

33

IV

6

6

The general process for rectal cancer detection and treatment is captured in Figure 2.
The process consists on first detecting and diagnosing the cancer, determining the stage of the
cancer, and selecting the treatment (two or more types of treatment may be combined or used
in sequence) based on the cancer stage prognosis and physician’s expertise. After treatment,
follow up and monitoring is recommended to assess treatment effectiveness and as a
preventive measure. In practice, there are algorithms in place that suggests the treatment
combination based on the cancer stage and cancer type. Patients with rectal cancer stage II
and III are recommended to have neoadjuvant therapy, as presented by treatment selection
2

algorithm for rectal cancer patients created by the MD Anderson Cancer Center [6]. Each
process component is described in detail in the next few sections.
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Figure 2 Rectal cancer detection and staging process

1.1.1 Rectal Cancer Diagnosis
Most people in early colon or rectal cancer stages do not experience the symptoms of
the disease. Thus, screening tests are recommended to detect and diagnose the cancer before
it further progresses. One or more of tests used to detect and diagnose colon and rectal cancer
include [7]:
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·

Endoscopic tests are nonsurgical procedures to examine and remove suspicious tissue or
polyps. Depending on how far up the colon is examined, three tests are performed:
proctoscopy to view the rectum; sigmoidoscopy to view of the rectum and lower colon;
and colonoscopy to view the entire colon

·

Endoscopic ultrasound: a picture (sonogram) is obtained by bouncing high-energy sound
waves (ultrasound) off internal organs

·

Imaging tests infuse energy through a patient and can show abnormal body structures.
Changes in energy patterns are captured to create an image or picture that is reviewed
by a physician and include: computed tomography scan (CT), magnetic resonance
imaging scan (MRI), and positron emission tomography scan (PET)

·

Digital rectal exam

·

Carcinoembryonic antigen (CEA) measures the quantity of this protein in the blood of
patients who have may have colon or rectal cancer

1.1.2 Staging
Staging is the process of determining the spread and extent of the cancer tumor once it
has been diagnosed. It is based on the results of the physical exam, biopsies, blood and
imaging tests. The American Joint Committee on Cancer (AJCC) staging system, also known as
the TNM system, is the tool most commonly staging used for colorectal cancer [2]. The TNM
consists of three key elements: ‘T’ defines how much the tumor has grown into the wall of the
intestine; ‘N’ defines the extent of spread to other lymph nodes; and ‘M’ defines whether the
cancer has metastasized to other organs of the body
Once the patient’s T, N and M categories have been determined, a stage grouping (from
stage I to stage IV in Figure 2) is determined from the least advanced to the most advanced
stage. The TNM combinations for each cancer stage are presented in Appendix A.
4

1.1.3 Treatment Options
There are different types of treatment for rectal cancer, some are standard practice and
others are being tested in clinical trials. According to the National Cancer Institute (NCI), four
types of standard treatment are used: surgery, radiation therapy (RT), chemotherapy, and
targeted therapy [8]. There treatments can be performed separately or combined as shown in
Figure 2. The oncologist will select the best therapy based on the type of cancer, stage and
location of the tumor.
The primary treatment used in rectal cancer is surgical resection [9]. According to the
NCI, local excision of clinical tumors is commonly used for selected patients in rectal cancer
stage T1. For higher stages of rectal cancer, a total mesorectal excision (TME) is the treatment
of choice. Since the introduction of TME for rectal cancer, reduced local recurrence rates and
improved oncologic outcomes have been observed [10]. Depending on the surgeon’s
experience, the rate of complications, such as blood loss and anastomotic leaks, are low.
Furthermore, radiotherapy before surgery appears to benefit patient outcomes even with
improvements in surgical technique [10].
RT is the most commonly prescribed treatment in rectal cancer treatment.
Approximately 50% of cancer patients will receive RT alone or in combination with other
treatments [11]. When used before surgery, the goal is to shrink the tumor to make surgery or
chemotherapy more effective. When used afterward, it is used to destroy any cancer cells that
might remain after surgery [6]. There are two basic types of RT:
·

External beam radiation is administered by a machine and rotates around the patient’s
body to deliver a high dose of radiation directly to the tumor (some of the tissue around
the tumor can also be affected).
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·

Internal radiation, also known as brachytherapy, consists of a radiation source that is
implanted in the body at the tumor site. Based on the type of the tumor, the appropriate
equipment is selected for treatment.
A combination of radiation and chemotherapy before radiation (also known preoperative

chemo-radiation (CRT) or neoadjuvant therapy) has become the standard of care for patients
with clinically staged T3–T4 or node-positive disease based on the results of clinical trials [9].
CRT may be given before surgery to shrink the tumor, make it easier to remove the cancer, and
lessen problems with bowel control after surgery. Even if all the cancer that can be seen at the
time of the surgery is removed, some patients may be given radiation therapy or chemotherapy
after surgery to kill any cancer cells that are left. Treatment given after the surgery to lower the
risk of relapsing is called adjuvant therapy.
1.1.4 Adverse Effects of Radiation Treatment
For patients with rectal cancer stage II and III, neoadjuvant treatment with RT and 5FU-based chemotherapy is preferred compared to adjuvant therapy in reducing local recurrence
and minimizing toxicity [12]. However, there are specific challenges and adverse effects
associated with the RT in rectal cancer patients. These include:
·

Gastrointestinal disorders: diarrhea, bleeding, abdominal pain and obstruction due to
stenosis or adhesions

·

Genitourinary dysfunction: incontinence, retention, dysuria, frequency and urgency

·

Sexual Dysfunction: in males, a long-term deterioration of ejaculatory and erectile
function; and in females, RT was associated with vaginal dryness and diminished sexual
satisfaction

·

Second Cancers: risk of second cancers from organs within or adjacent to the irradiated
target. The most common second cancers include gynecologic and prostate.
6

RT after or before surgery treatment has negative effects on toxicity and the quality of
life of the patient; therefore, treatment options should be discussed with the patient.
1.2 Personalized Medicine
Personalized medicine refers to the use and implementation of the patient’s unique
biologic, clinical, genetic and environmental information to make decisions about their
treatment or course of action [13]. Cancer therapy is implemented on a watch-and-wait basis
for most patients. Although an individual’s clinical information (cancer stage) is used to decide
which regimen is likely to work best, only data referring to outcomes of larger groups of
patients are currently considered. Under the umbrella of personalized medicine is genomic
medicine.
Genomic medicine refers to “the use of information from genomes (from humans and
other organisms) and their derivatives (RNA, proteins, and metabolites) to guide medical
decision making” [13]. The discovery of patterns in gene expression data and examining a
person’s genome makes possible to make individualized risk predictions and treatment
decisions. A patient predisposition to treatment and health states can now be characterized by
their molecular information, and useful classifiers and prognostic models can be developed to
more strategically make decisions.
There has been a significant improvement in sensitivity as DNA microarray technology
continues to advance. DNA microarray and gene expression profiles data have made possible to
understand and make new discoveries at the molecular level regarding human conditions and
diseases, especially cancer [14]. However, a challenge facing this area of study is the
complexity and amount data across multiple samples.
This research is motivated by the question of whether it is possible to determine which
patients will more likely benefit from receiving RT as part of their cancer treatment. Clinical
7

decision-making regarding RT is still based on estimated overall level of tumor aggressiveness,
but current decision models are not personalized for predicting the benefit from RT for a
specific patient [15]. Torres-Roca developed and validated a system biology model of cellular
radiosensitivity which lead to the discovery of novel radiation specific predictive biomarkers
[16]. The clinical applications of this type of personalized predictive model have the potential to
identify patients likely to benefit from certain treatment and determine a more effective
treatment strategy.
1.3 Patient-Centered Decision Making
There has been an increasing trend in the way patients are moving from being a passive
actor of their disease management process to actively making decisions regarding their
treatment. It could now be expected that patients will at least give true informed consent to
their treatment, if not actually making such treatment decisions themselves. Depending in the
stage of the cancer, the decision of receiving a treatment is a matter of several factors and
implications that influence the patient to accept or reject treatment. Further treatment may
prolong life or relieve symptoms, but in some cases will not eradicate the disease. A trade off
must be made between possible benefits and likely side effects [17].
It is still unclear to what extent patients are involved in their decision making and how
they can resolve their personal uncertainty regarding their treatment options [18]. Kiesler,
2006 [19], reviewed studies regarding the involvement of patients in the decision making
process, it was found that although a large proportion of patients want to be fully informed and
actively participate in their treatment decisions with their physicians, a considerable proportion
of patients prefer to have little to no detailed information about their condition or involvement
in medical decisions. Moreover, this shared decision process is dynamic in the sense that it will
vary depending on the patient preferences, time with condition, and stage among others.
8

This work is based on the idea that the decision making process should consider the
individual patients preferences for which treatment, if any, should be selected. Different
significant predictors for overall survival, quality of life, cost-effectiveness, and response to
treatment include individual patient genomic profile factors, prognostic biomarkers, and socioeconomical patient characteristics. This information can help the patient make informed
decisions regarding their treatment, based on their individual preferences and personal
situation.
1.4 Review of Literature
This review of the literature concentrates on decision models used to select viable
treatments for patients with cancer. Databases in the area of engineering and medicine were
used to search articles with publication date from 01/01/2000 until 05/01/2014: Compendex
(engineering village), PubMed, Medline CSA, ScienceDirect, and Web of science. Keywords used
were: (Cancer) AND [(Decision Model) OR (treatment selection)].
A large of proportion of articles found in cancer decision making focus in determining
which prognostic factors and biomarkers are the most significant predictors in the assessment
of different outputs (e.g. Survival, Recurrence rate and chances of metastasis). The
information, criteria, methods and objectives used in the models to make the treatment
selection decision are listed in Table 2.
The objectives and criteria used in cancer treatment selection models involve intrinsic
trade-offs between survival and quality of life. Summers (2007) assessed trade-offs between
quantity and quality of life particular to prostate cancer patients as well as among different side
effects to determine which treatment would be optimal for a specific patient [20]. [21], [22],
[23], [24], used a utility score and defined it as the relative value patients assign to potential
health states. Utility values were obtained from interviews or the literature. Some of the
9

treatment complications considered include: sexual dysfunction, urinary symptoms bowel
dysfunction, and death. Szumacher, 2005 [25], implemented a decision model based on
patients preferences in regards to convenience of treatment plan, pain relief, overall quality of
life, individual’s chances of survival and out-of-pocket costs. Survival, chance of metastasis and
risk of relapse are usually compared to quality of life measures: In [26] and [27] models are
evaluated based on the probability of the cancer relapsing after an amount of time, and [20],
[24], [27] assessed the chance of the cancer spreading to other organs as decision criteria. On
the other hand, Another number of articles concentrated specifically on the cost effectiveness of
various strategies [28], [29], [27]. Van Gerven, 2007 [30], focused on the maximization of
patient benefit, while simultaneously minimizing the cost of treatment.
Among the methods utilized in the literature, different types of Markov decision analysis
framework were the most used [20], [21], [22], [23], [29] and [30]. A Markov decision process
extends a Markov chain by allowing actions and rewards to incorporate both choice and
motivation, also the Markov property ensures that the future state is independent of the past
state given the current state of a random process. In [28], [29], [27] decision tress and costeffectiveness analysis as a strategy to select strategies. Multi-criteria optimization models were
used in [31], [32] to find the best dose–volume histogram (DVH) values by varying the dose–
volume constraints on each of the organs at risk (OARs). Other methods used include: neural
networks and multivariate statistical analysis [25]. In most cases, patient’s preferences are not
considered in these models to make individual recommendations. Therefore, future analyses
need to provide outcomes stratified by more specific risks and preferences.
The data used as inputs in the models include tumor anatomy factors, patients’
characteristics, and cost estimates. Tumor anatomy is also considered using the TNM staging
system in various studies [24], [28], [29], [30]. Gleason score and prostate-specific antigen
10

(PSA) are important input for prostate cancer treatment selection [21], [20], [22], [24]. Age is
the most commonly patient factor considered in the models [21], [20], [22], [24], [30], [23],
[28], [26], [25]. Other patient and health factors include: gender, race, treatment history,
comorbidities and laboratory test results.
1.5 Problem Statement
Treatment decision making for cancer is complex. Every patient is unique with their own
genetic traits, predisposition to side effects and preferences. The patient and clinician’s
subjective judgment plays a vital role in making sound treatment decisions. Furthermore,
various patient-specific factors make it difficult to objectively and quantitatively compare various
treatment decisions.
Radiation Therapy (RT) is the most commonly prescribed single agent in cancer
therapeutics. Approximately, half of cancer patients receive RT as part of their treatment. There
has been great improvement in the quality and effectiveness of RT delivery in the last years.
Unfortunately, neoadjuvant CRT is not beneficial for all patients. The treatment response ranges
from a pathologic complete response (pCR) to a resistance. It is reported that only 10 to 20
percent of patients with advanced rectal cancer show pCR to neoadjuvant CRT. Nowadays,
patients with no response or minimum tumor response to neoadjuvant CRT before its initiation
are not being identified [33].
We are entering in a new era of personalized, patient-specific care, and with the advent
of low-cost individual genomic and proteomic analysis, we are on the path of employing
patient’s biologic data to systematically predict the best course of therapy [34]. Identifying
patients that potentially could benefit from CRT and justifying a given treatment path will
hopefully minimize side effects caused by the current treatment practices. This is the based
premise for the work presented in this dissertation.
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Table 2 Summary of cancer treatment selection models in the literature
Data Considered in Decision Models
Tumor Anatomy

Patients characteristics

Gleason Grade

[21], [20], [22], [24],

TNM or mass

[30], [28], [24], [29]

PSA

[20], [24]

Age

[21], [20], [22], [24], [30], [23], [28],
[26], [25]

Gender

[30], [26], [25]

Race

[26], [25]

Treatment history

[30], [26]

Comorbidities

[21]

Laboratory results

[26]

Costs

[30], [23], [28], [29], [25], [27]

Decision Criteria
Quality of life

[20], [22], [30], [23], [24], [25]

Patient Utility

[21], [22], [30], [23], [32]

Survival

[20], [28], [24], [29], [25]

Cost effectiveness

[23], [28], [29], [27]

Chance of metastasis

[20], [24], [27]

Risk of relapse

[26], [27]

Disutility

[20]

Tumor Response

[30]

Planning target volume (PTV)

[31], [32]

Methods
Markov framework

[21], [20], [22], [30], [23], [29]

Cost-Effectiveness analysis

[23], [28], [29], [27]

Decision trees

[28], [29], [27]

Bayesian Networks

[30], [24]

Optimization modeling

[31], [32]

Multivariate analysis

[25]

Neural Networks

[26]
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1.6 Global Research Objectives
The general objectives of this work are two-fold:
·

Objective 1: Build and validate a prediction model based on the gene expression profiles
of a sample of cell lines for the response of a patient to RT (Radiosensitivity) using their
genomic information.

·

Objective 2: Integrate measures of the patient’s clinical information: survival, biological
characteristics and anticipated adverse effects into a patient-centered prescriptive model
that determines the most appropriate course of action at a given stage (II and III) for
rectal cancer.

1.7 Document Organization
This dissertation is organized in four chapters (See Figure 3). Chapter 1 presents a
review of the literature, defines the problem, and presents the objectives and hypotheses of
this research. Chapter 2 presents a prediction model of radiosensitivity of cancer tumor cells in
response to radiation therapy using gene expression profiles; in Chapter 3, a fuzzy approach for
treatment selection in cancer treatment is developed considering various criteria; and Chapter 4
presents the conclusions, limitations and opportunities future research.
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CHAPTER 2: PREDICTION OF RADIOSENSITIVITY OF CANCER TUMOR
CELLS IN RESPONSE TO RADIATION THERAPY USING GENE EXPRESSION
PROFILES
2.1 Introduction
Radiation therapy (RT) is the most commonly prescribed cancer treatment and can be
effective in curing cancer. The success rates for RT are comparable with those achieved with
surgery in some cancers (prostate , head and neck and cervical cancer) [35]. Over the past
decades, RT effectiveness has improved by the discovery of physical approaches that optimizes
the radiation dose to tumors and space normal tissues. With the introduction of microarrays and
the use of gene expression to identify features in medical outcomes, identification of gene
signatures and pathways activated in the response of cells to radiation can result in the
development of treatment options which gene expression is controlled within the irradiated
tumor (e.g. BUdR and IUdR were among the first classes of biological agents analyzed as
radiosensitizers to enhance the effects of radiotherapy treatment) [36].
Decision making and treatment selection in radiation oncology is subjective and based
on clinic-pathological features of a large group of patient outcomes [16]. In personalized
medicine, the objective is to select the most appropriate course of treatment that fits an
individual patient’s needs and characteristics. Genomic medicine technological advancements
has now the potential of predicting a patient predisposition to RT. Microarrays technology is one
of the most widely adopted methods of genomics analyses. Microarrays experiments generate
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functional data on a genome-wide scale, and can provide important data for biological
interpretation of genes and their functions [37].
The complexity and dimensionality of the data generated from gene expression
microarray technology requires advanced computational approaches. Machine learning and
supervised learning methods provide tools to develop predictive models from available data,
and it is effective when dealing with large amounts of biological data. In this dissertation, we
present a methodology to organize and analyze gene expression data and test whether it
results in an accurate predictive model of tumor radiosensitivity.
Machine learning refers to the type of computational techniques that are used to
develop a “model” from a set of observations of a system. The term “model” assumes that
there exists an approximate relationships between the parameters considered in the system.
The goal is to predict a quantitative (regression) or qualitative (classification) outcome using a
set of attributes or features [38]. Consequently, supervised learning refers to the subset of
machine learning methods where the input–output relationship is assumed to be known.
Supervised learning is commonly used in the computational biology area ranging from
gene expression data to analysis of interactions between biological subjects [38]. Some of the
most commonly used supervised learning methods used in computational biology include:
neural networks, support vector machine, logistic regression, multivariate linear regression,
decision tree-based models and ensembles (random forest). A review of these methods is
presented in the following section.
This chapter consists on the development of a personalized diagnostic tool to predict
radiotherapy (RT) efficacy using the patient genomic information and estimate likelihood of
response to RT of an individual patient. In the next chapter, the results of this model will be
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implemented into a decision model with the objective of guiding the patient and physician
decision on the selection of a cancer treatment strategy.
2.2 Review of Prediction Models in Computational Biology
A summary of the methods, relevant literature, strengths, limitations and opportunities
are presented in Table 3. Methods used in prediction models for various areas of computational
biology were categorized into: artificial neural networks; support vector machines; decision
tree-based methods; and logistic regression.
Artificial neural networks (ANN) and support vector machines are among the most
commonly used black box machine learning tools in the literature. ANN-based approaches may
be applied for classification, predictive modelling and biomarker identification within data sets of
high complexity [39]. More recent studies using ANN approaches in system biology include: a
validated a reduced (from 70 to 9 genes) gene signature capable of accurately predicting
distant metastases by Lancashire et al [40]; a model to predict Parkinson’s disease using microarray gene expression data by Sateesh Babu et al [41]; and a gene expression-based model to
select 20 genes that are closely related to breast cancer recurrence by Chou et al [42].
The support vector machine (SVM) algorithm consists on a hyperplane or a set of
hyperplanes in a high-dimensional space, which are then used for classification or regression
[43]. Support vector machines (SVM) have a number of mathematical features that make them
attractive for gene expression analysis due to its ability of dealing with large data sets with high
data dimensionality, ability to identify outliers, ﬂexibility in choosing a similarity function and
sparseness of the solution [44]. According to Statnikov et al, multi-category SVM are the most
effective classifiers in performing accurate cancer diagnosis using gene expression data [45].
However, most studies find that the main limitations of SVM are the lack of interpretability of

17

the results and estimates for the underlying probability, and the heuristic determination of the
Kernel parameters.
Table 3 Summary of prediction models in computational biology
Method

Artificial
neural
networks

Support
vector
machines
and kernels

Decision
tree-based
methods
and
Random
forest

Logistic
regression

Relevant
Literature

[40]–[42],
[46]–[50]

[44], [45],
[51]–[54]

· Can process data
containing non-linear
relationships and
interactions
· Can handle noisy or
incomplete data
· Capable of feature
selection in high
dimensional data
· Good predictive
performance

· (L)Hard to interpret
(O) Sensitivity analysis and rule extraction can be used
extract knowledge
· (L) Prone to over-fitting
(O) re-sampling and cross-validation can be used to
address this issue
· (L) Multiple solutions associated with local minima

· Can process data
containing non-linear
relationships and
interactions
· Can provide a good
out-of-sample
generalization
· Optimality problem is
convex

· (L) Large margin classifiers are known to be sensitive
to the way features are scaled
(O) data normalization
· (L) sensitive to unbalanced data
(O) assign a different misclassification cost to each
class
· (L) Kernel parameters are data-dependent
(O) Try a linear and a non-linear kernel
· (L) Prone to over-fitting
(O) Local alignment kernel
· (L) Classification performance of a single tree lower
than other methods
(O1) Classification performance could be improved by
combining more than two features at each node
(O2) Classification performance is improved by
aggregation of predictions by ensembles
· (L) Decision trees are sensitive to the training data set
used and overfitting
(O) Random forest use bootstrapping to estimate
outcomes by aggregation of difference trees
· (L) Inadequate to perform regression of continuous
values
(O) Tree ensembles use a large number of tree to
obtained aggregated solutions and good performance
· (L) LR can only be used to predict discrete functions
· (L) Parameter estimation procedure of LR assumes an
adequate number of samples for each combination of
independent variables
(O) Needs to make sure a large sample size and
determine adequate number of samples for each
combination
· (L) Independent binary variable must be balanced
(O) Resample the available data to obtain a balanced
dataset

· Readily understandable
Interpretable
· Ability to rank the
attributes according to
their relevance in
predicting the output
[55]–[64]

[65]–[74]

Limitations (L)
Opportunities (O)

Advantages

· Most commonly used
method in
classifications problems
· Often used as
benchmark to compare
models
· Can handle nonlinear
effect, interaction
effect and power terms
· Readily understandable
Interpretable
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In models using logistic regression for classification, the outcome of interest is assumed
to be binomially distributed with the logistic function f(y) = 1/(1+exp−y) . The variable y is a
measure of the contributions of the parameters y = β0+β1x1+...+βnxn, where β0 is a constant
term and the β1, β2, ..., βn are regression coefficients. Zhu and Hastie [69] present a summary
of the implementation of a penalized logistic regression (PRL) model and an algorithm using
univariate ranking (UR) and recursive feature elimination (RFE) to select a fewer genes than
other methods. Among the extensions of logistic regression models, Shevade et al. [70]
implements a sparse logistic model to suggest a gene selection method that is efficient and can
be applied to identify marker genes. Finally, Chen et al [74] conducts a review on variations of
logic regression: logic feature selection, Monte-Carlo logic regression, genetic programming for
association studies, and modified logic regression-gene Expression Programming, and evaluates
the performance of each method using genotype data.
The origin of tree-based learning methods is often credited to Hunt [75], but the
method became recognized in the field of statistics by Breiman et al. [76] with the Classification
And Regression Trees (CART). Since then, more decision-tree based methods have been
proposed to improve the prediction accuracy by aggregating the predictions given by several
decision trees for the same outcome. Although decision tree models were originally designed to
address classification problems, they have been extended to handle Univariate and multivariate
regression. Random forests (RF) models [77] is a randomization method that modifies the
node splitting of the CART procedure as follows: at each node, K candidate variables are
selected at random among all input candidate variables, an optimal candidate test is found for
each of these variables, and the best test among them is eventually selected to split the node
[78].
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This study develops and compares a number of supervised learning methods
appropriate to the structure and objectives of the models. Based on the performance of the
models, a prediction model trained in tumor cell gene expression data is validated in two
independent clinical outcomes datasets for patients that received pre-operative RT.
2.3 Objectives
The objective of this research study is to predict radiation sensitivity (Radiosensitivity),
defined based on cellular clonogenic survival after 2 Gy (SF2) for 48 cell lines (see Table 4), and
estimates as in equation (1). Since gene expression profiles are available for all cell lines, gene
expression is used as the basis of the prediction model.
𝑆𝐹2 =
·

𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
𝑡𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑝𝑙𝑎𝑡𝑒𝑑 × 𝑝𝑙𝑎𝑡𝑡𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦

(1)

Hypothesis 1: A radiosensitivity cell-based prediction model can be validated using
clinical patient data from rectal and esophagus cancer patients that received RT before
surgery.

·

Hypothesis 2: A radiosensitivity genomic-based prediction model could identify patients
with rectal cancer that may benefit from RT treatment by assigning higher values of SF2
to radio-resistant patients and lower values of SF2 to radio-sensitive patients.
Radiosensitivity is defined based on cellular clonogenic survival after 2 Gy (SF2) for 48

cell lines. Since gene expression profiles are available for all cell lines, gene expression is used
as the basis of the prediction model. Radiosensitivity prediction has been studied by [16], [79]
where a clinically validated radiosensitivity index (RSI) has been defined to estimate
radiosensitivity. The proposed approach differs from [16], [79] the response SF2
transformation process and in the gene expression selection process, using a statistically
procedure versus a biological feature selection approach.
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2.4 Methods and Materials
Cell lines are used to construct the prediction model and were obtained from the NCI
[35]. Cells were cultured as recommended by the NCI in Roswell Park Memorial Institute
medium (RPMI) 1640 supplemented with glutamine (2 mmol/L), antibiotics (penicillin/
streptomycin, 10 units/mL) and heat-inactivated fetal bovine serum (10%) at 37ºC with an
atmosphere of 5% CO2.
Analyses using microarrays technology has been widely adopted for generating gene
expression data on a genomic scale. Gene expression profiles were from obtained from
Affymetrix U133plus chips [80] from a previously published study by Eschrich, 2009 [81].
2.4.1 Output
A transformation function (equation 2) is applied to the SF2. Originally SF ranges
between 0 and 1; with the transformation functions, SF2 can range between -∞ and ∞. The
objective of this transformation is to enhance the extremes values of SF2 (radio-sensitive and
radio-resistant responses). The transformation follows equation 2 and represented in Figure 4:
𝑇𝑆𝐹2 =

(2)

1
1
−
1 − 𝑆𝐹2 𝑆𝐹2

10
1/(1-sf2)-1/sf2
5

t_sf2

0

-5

-10

-15

-20

0

0.1

0.2

0.3

0.4

0.5

0.6

0.7

0.8

0.9

sf2

Figure 4 SF2 and transformed SF2
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The survival fraction at 2 Gy (SF2) of 48 human cancer cell lines used in the regression
model was obtained from Torres-Roca, 2005 [35] and are presented in Table 4.
Table 4 SF2 measured values for 48 cell lines in the database
Cell Line

Tissue of
Origin

Measured
SF2

0.632

Leuk_ccrfcem

Leukemia

0.185

Breast

0.79

Leuk_hl60

Leukemia

0.315

Breast_mcf7

Breast

0.576

Leuk_molt4

Leukemia

0.05

Breast_mdamb231

Breast

0.82

Melan_loximvi

Melanoma

0.68

Breast_t47d

Breast

0.52

Melan_m14

Melanoma

0.42

Breast_mdamb435

Breast

0.1795

Melan_malme3m

Melanoma

0.8

Cns_sf268

CNS

0.45

Melan_skmel2

Melanoma

0.66

Cns_sf539

CNS

0.82

Melan_skmel28

Melanoma

0.74

Cns_snb19

CNS

0.43

Melan_skmel5

Melanoma

0.72

Cns_snb75

CNS

0.55

Melan_uacc257

Melanoma

0.48

Cns_u251

CNS

0.57

Melan_uacc62

Melanoma

0.52

Colon_colo205

Colon

0.69

Ovar_skov3

Ovarian

0.9

Colon_hcc-2998

Colon

0.44

Ovar_ovcar4

Ovarian

0.29

Colon_hct116

Colon

0.38

Ovar_ovcar5

Ovarian

0.408

Colon_hct15

Colon

0.4

Ovar_ovcar8

Ovarian

0.6

Colon_ht29

Colon

0.79

Ovar_ovcar3

Ovarian

0.55

Colon_km12

Colon

0.42

Prostate_du145

Prostate

0.52

Colon_sw620

Colon

0.62

Prostate_pc3

Prostate

0.484

Nsclc_a549atcc

Non-Small Cell Lung

0.61

Renal_7860

Renal

0.66

Nsclc_ekvx

Non-Small Cell Lung

0.7

Renal_a498

Renal

0.61

Nsclc_hop62

Non-Small Cell Lung

0.164

Renal_achn

Renal

0.72

Nsclc_hop92

Non-Small Cell Lung

0.43

Renal_caki1

Renal

0.37

Nsclc_ncih23

Non-Small Cell Lung

0.086

Renal_sn12c

Renal

0.62

Nsclc_h460

Non-Small Cell Lung

0.84

Renal_uo31

Renal

0.62

Cell Line

Tissue of Origin

Breast_bt549

Breast

Breast_hs578t

Measure
d SF2
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2.5 Feature Selection
Standard prediction models and variable reduction methods face an important challenge
with the dimensionality of the data. This is the case for the area of genomic applications where
the number of genes is considerably higher than the samples available to study them. In this
problem, a total of m = 54,675 potential candidates (gene expression) are considered to be
part of the prediction models with a total of n = 48 observations tumor cells. The most
commonly used approaches, such as PCA, require for n > m. However, this problem shows
m>>n. Thus, a methodology to reduce the sample size and to identify features that are
statistically independent (low correlation values) is recommended. The objectives of the
dimension reduction procedure presented here are to:
·

Identify independent (not highly correlated) features

·

Improve performance of prediction models by removing irrelevant predictors

·

Improve efficiency of modeling using fewer features

·

Reduce the selection of effects whose influence on dependent variable is mostly random
Our approach is an Univariate method that selects the most relevant (statistically

significant) features one by one and excluding the rest, as show in [82]. This technique is
computationally simple and fast to process high-dimensional datasets, and it is independent of
the classification/regression models. When using this procedure, feature dependencies are
ignored. Thus, a step to extract independent features has to be included (step 5 below). The
procedure to select the candidate predictors include:
1. Start with 54,675 gene expressions:
2. Merge repeated gene expression by replacing with average
3. Normalize labels in datasets to create a single data file (Cell-lines have different labels in
the various files)
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4. Conduct response variable transformation
5. Univariate ranking: perform univariate regression with each gene versus T_SF2:
6. If (p-value >= 0.0001) then Variable is kept in the model; Otherwise, variable is
excluded
7. Identify independent variables:
7.1 Estimate correlation matrix
7.2 If (correlation coefficient >= 0.9) then select gene with higher R2 in reg for t_sf2 in
cluster
7.3 Otherwise, consider this variable “independent”.
8. End with the reduced data set containing 169 features (gene expressions)
The dimension reduction process presented in this study is also compared with two
other feature selection methods such support vector machines. The subset of selected variables
from the 54,675 gene expression probeset ID did not match previous subset selected, and
selected subset was much larger with 12,399 (highly correlated) gene expression probeset IDs.
Since subset of selected features was different for all methods there is no evidence to support
one method over the other. The support vector machine variable selection steps used for this
approach has been documented by Rakotomamonjy (2003) in the Journal of Machine Learning
Research [83].
2.6 Predictive Model Development
Predictive models are developed and compared based on their performance. The
experimental design of the models is presented in Figure 5. The process to build, test and
validate the models has been used in the literature of supervised learning methods in
computational and systems biology [38], and it can be summarized as follows:
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1. Learning sample (LS) consists of 48 cell lines
2. Build model on LS using the default parameterization of the method using crossvalidated: 2/3 learning sample (ls.s1), 1/3 testing sample (ls.s2)
3. Evaluate the accuracy of model on the test sample ls.s2
4. If the accuracy results are not acceptable, then play with different values of the
parameter K (for random forest)
5. Select the value K* that leads to performance on S2.
6. Build selected model on LS and validate predictions on TS to get an estimate Accfinal of
its accuracy. There are two TS datasets and will be described in the validation section.

N = 48 cell lines

Validation Set (VS)
Clinical cohort(s) of
cancer patients that
received RT before
Surgery

Learning Set (LS)
Data is split
randomly

2/3

Training Set
(ls.s1)

1/3

Accu. test Set
(ls.s2)

Multivariate
Regression with
2-way
interactions
Decision Tree
with recursive
Partitioning
(CART)

Test for
accuracy

Select most
accurate
model and
train on LS

Random Forest

Figure 5 Experimental design
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Validate on VS

In the selection of a prediction model, there is tradeoff between simplicity and
wholeness. Simpler models can be more understandable, computationally tractable. On the
other hand, more complex models tend to ﬁt the data better and to capture more information
from available data. Two simple models (a Multivariate regression model and a decision tree
model) and a more complex model (random forest) are created and compared to select the
most appropriate model in the prediction of radiation sensitivity.
2.6.1 Multivariate Regression with 2-way Interactions
Linear regression is a method used in building models from data for which dependencies
can be closely approximated [84] and predicting the value of a response (y) from a set of
predictors (xi). Let x1,x2,…,x169 be a set of 169 predictors believed to be associated with the
transformed response T_SF2. The linear regression model for the jth has the form given in (3):
𝑇_𝑆𝐹2𝑗 = 𝛽0 + 𝛽1 𝑥𝑗1 + 𝛽2 𝑥𝑗2 + ⋯ + 𝛽169 𝑥169 + 𝜖𝑗

(3)

The matrix notation is ŷ = Xβ where 𝜖 is a random error with 𝐸(𝜖𝑗 ) = 0, 𝑉𝑎𝑟(𝜖𝑗 ) = 𝜎 2 ,
𝐶𝑜𝑣(𝜖𝑗 , 𝜖𝑘 ) = 0 ∀𝑗 ≠ 𝑘, and 𝛽𝑖 , 𝑖 = 0,1, . . ,169 are the regression coefficients. The approach to
estimate the vector 𝛽′𝑠 in this study is the least square estimation: The value of 𝛽 that
minimizes the sum of square residuals (Y − Xβ)′(Y − Zβ) and the decomposition is given by (4):
𝑛

∑(𝑦𝑗 − 𝑦̅)2 = ∑(𝑦̂ − 𝑦̅)2 + ∑ 𝜖̂ 2
𝑗=1

𝑗

(4)

𝑗

The goodness of ﬁt (GOF) of the model is measured by the proportion of the variability
that the model can explain given by R2. The formulation and motivation of the use of R2 and
other performance measures of GOR have been extensively addressed in the literature [85].
The creation of the multivariate regression model allowed for 2-way interactions to be
considered as predictors in the regression model. The steps to build the models are as follows:
(1) the model was coded using proc glmselect in SAS 9.3. (2) The selection process consisted
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on a stepwise forward selection (effects already in the model do not necessarily stay as the fit is
iteratively tested considering all candidate variables at every step). The decision criteria used
considers the optimal value of the Akaike information criterion (AIC) and the adjusted R2 to
access the trade-off between the goodness of fit of the model and the penalization number of
predictors in the system (overfitting). The AIC value is given by 𝐴𝐼𝐶 = 2𝑘 − 2𝑙𝑛(𝐿), where k is
the number of parameters and L is the value of the likelihood function.
The value of the adjusted R2 is also presented in Figure 6. It can be observed that the
value for the adjusted R2 does not considerably improve after step 7; therefore the total
number of interaction effects in the model is eight. A summary of the selection process and
significant predictors’ interactions, parameter estimates and performance measures (AIC and
adjusted R2) can be found in Table 5.
Table 5 Multivariate regression model selection

Step

Interaction of effects
(gene expression)

Parameter
estimate

Number of
effects in
model

adjusted
R2

AIC

0

intercept

1

58.207248

1

0

184.8924

1

222868_s

1554636_a

-1.976624

2

0.6657

133.5468

2

226367_a

244039_x_

-1.916222

3

0.7498

120.9651

3

208923_a

1557248_a

-0.187086

4

0.7967

112.4197

4

243559_a

1564276_a

1.555853

5

0.8443

101.1404

5

236687_a

1564128_a

-2.664955

6

0.8766

91.5949

6

215703_a

1557062_a

0.833148

7

0.897

84.6667

7

202252_a

238735_at

-0.132294

8

0.9112

79.3727*
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Figure 6 Model performance in terms of adjusted R-square

2.6.2 Classification and Regression Trees
The description of the decision tree methodology is included in this manuscript since it is
the basis of the random forest methodology (a set of trees). A decision tree induction is a
method of data analysis that maps the dependency relationships in the data [84], and it is
sometimes subsumed by the category of cluster analyses. The goal with CART is to build a
regression tree and predict radiosensitivity (SF2) based on the gene expression profiles
available using recursive partitioning or rpart in R [86]. The following steps are followed to build
the tree in rpart:
The Splitting criteria, as proven by Breiman et al [87], of a node A into two sons AR and
AL is given by (5):
𝑃(𝐴𝐿 )𝑟(𝐴𝐿 ) + 𝑃(𝐴𝑅 )𝑟(𝐴𝑅 ) ≤ 𝑃(𝐴)𝑟(𝐴)

(5)

where: P(A) is the probability of A for future observations, and r(A) is the risk of A. However,
rpart considers measures of impurity or diversity for the note splitting criteria.
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Let 𝑓 be the impurity function deﬁned by (6):
𝐶

𝐼(𝐴) = ∑ 𝑓(𝑝𝑖𝐴 )

(6)

𝑖=1

where 𝑝𝑖𝐴 is the proportion of the elements in A that belong to class i. Therefore, if I(A) = 0
when A is pure, 𝑓 must be concave with f(0) = f(1) = 0. the split with the maximal impurity
reduction (the Gini or information index) is used.
The measure of impurity can be implemented using the generalized Gini index or alert
priors. This model was implemented in rpart software package in R 2.15.1, and only altered
priors is available [86] for the analysis. The model building process also estimates a measure of
importance for the predictors in the decision tress based on the sum of the goodness of split or
adjustment agreement. This is very useful when two variables are similar and one must be
selected to enter the models.
Cross-validation can be performed in decision trees using recurve partitioning. The data
is divided into n groups. The model is trained in all groups except for one, the predicted class is
computed, and it summed over all groups for each parameter estimate. The chosen tree will be
the one with the complexity parameter with the smallest risk, computed in the full dataset.
Finally, decision trees can be built to address classification or regression problems. For
regression problems, as is the case for the problem considered in this research, the splitting
criterion used to decide the best split for the predictor candidates is estimated by SST − (SSL +
SSR), where SST is the sum of squares for the node, and SSR, SSL are the sums of squares for
the right and left son. The decision tree model seeks to split the node in order to maximize the
between groups SS in the ANOVA method. The prediction error for a new observation is
estimated by (ynew- yavg).
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X_226367_at>=4.119
|
0.0778

X_201783_s_at>=7.754
-5.702

1.065

X_202123_s_at< 7.877
0.4162

3.739
X_202531_at< 7.484

-1.003

0.9485
0.434

2.198

Figure 7 Decision tree prediction model
2.6.3 Random Forest
Supervised learning provides techniques to learn predictive models only from
observations of a system and is therefore well suited to deal with the highly experimental
nature of biological knowledge [78].
Breiman’s Random Forests algorithm builds each tree from a bootstrap sample like
Bagging but modifies the node splitting procedure as follows: at each test node, K attributes are
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selected at random among all input attributes, an optimal candidate test is found for each of
these attributes, and the best test among them is eventually selected to split the node [88].
The prediction model for radiosensitivity was built using the randomforest package in R
[89]. The selected predictors (gene expression profiles), ranked in the order the variable
reduced prediction error, are presented in Figure 8. The algorithm used to build the prediction
model is summarized in Figure 9.

Figure 8 Variable importance based on entropy reduction
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Original Data
Draw Ntree
bootstrap samples
Bootstrap
sample 1

Bootstrap
sample i

Bootstrap
sample n

Choose mtry
predictors (p)
Grow regression
tree i
Predict on “out-ofbag” new data (i+1)

Aggregating the predictions
of the ntree trees
(i.e., majority votes for
classification, average for
regression)

Calculate “out-ofbag” error estimate

Try mtry = 1 to p

Select mtry to get
the maximum of the
out-of-bag accuracy

Try Ntree =
10:100:50000

Select Ntree to get
the maximum of the
out-of-bag accuracy

Figure 9 Random forest algorithm
2.7 Validation
The predictive models were validated in three independent datasets: a dataset of 20
patients with rectal cancer that received neoadjuvant treatment, and a dataset of 12
esophageal cancer patients that received neoadjuvant treatment. Clinical Outcomes are
classified into responder(R) and non-responder (NR).
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2.7.1 Rectal Cancer Dataset
The sample size consisted of 20 patients with rectal cancer. The results of the tests are:
test of ETA1 = ETA2 vs ETA1 not = ETA2 is significant at 0.0185 using the random forest model
and 0.003144 using regression model (See Figure 10 and Figure 11).

Figure 10 Multivariate regression prediction results on the rectal cancer dataset

Figure 11 Random forest prediction results on the rectal cancer dataset
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2.7.2 Esophageal Cancer Dataset
The sample size consisted of 12 patients with esophageal cancer. Test of ETA1 = ETA2
vs ETA1 not = ETA2 is significant at 0.026 using the random and 0.032 using regression model
(See Figure 12 and Figure 13).

Figure 12 Multivariate regression prediction results on the esophageal cancer
dataset

Figure 13 Random forest prediction results on the esophageal cancer dataset
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2.8 Discussion
In this study, the microarray gene expression data processing and prediction model is
built following four modeling parameters:
1. Response variable transformation: SF2 for 48 cancer cell lines was transformed using a
mathematical function to augment the lower and upper extremes (related to
Radiosensitive and Radioresistant cell lines) of the radiosensitivity/radioresistance
spectrum
2. Dimensionality reduction: candidate gene expression probesets were selected using a
univariate regression analysis with statistical significance (p <= 0.001)
3. Model building: Breiman’s Random Forest algorithm [77] which is an ensemble of
decision trees, was trained using the learning sample of the 48 human cancer cell lines
to predict the transformed SF2
4. Model calibration: statistically significant differences (p < 0.05) were found between the
median of the training set of the cell lines and the validation set of patients. We
estimated the calibration parameters based on the calculated difference in medians.
This study provides clinical support for a practical and novel assay to predict tumor
radiosensitivity. Due to the difference in experimental measurement in DNA microarray gene
expression values among different cohorts, calibration methods should be created to
standardize validation across different sites. Further testing of this technology in larger clinical
populations is supported.
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CHAPTER 3: A FUZZY APPROACH FOR TREATMENT SELECTION IN CANCER
TREATMENT
The objective of this research is to develop a decision support model that can determine
the most appropriate treatment strategy by combining clinical expertise and individual patient
preferences concerning the treatment options available and desired clinical outcomes. The
model based design and decision-making consists of a multiple-input/multiple-output (MIMO)
fuzzy logic controller (FLC). For this work, we extract the knowledge from historical data,
specific to colorectal cancer patients receiving radiation therapy and/or surgery from 2004 to
2010. The fuzzy system presented follows the theoretical structure presented by [90], and gets
expanded by using data driven expertise acquisition and inclusion of a preference measure. The
decision model and treatment strategy is evaluated using the following criteria: survival,
adverse events, and efficacy. Efficacy is measured in terms of patient’s response to radiation
therapy or radiosensitivity (the prediction model for radiosensitivity was discussed in Chapter
2). Finally, several patient decision options are presented and compared using sensitivity
analysis to present scenarios based on their individual characteristics and preferences.
This chapter is organized as follows. We first introduce basic FLC related concepts to be
used throughout this dissertation involving the definitions of a fuzzy sets, fuzzy input, fuzzy
output variables and fuzzy state space. Then, a review of the literature is presented that
focuses on fuzzy decision support models (FDSM) is presented, followed by the research
objectives and hypotheses. The FDSM approach and results are also included. Finally, the
chapter closes with the sensitivity analysis, conclusions and future research.
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3.1 Concepts in Fuzzy Logic
Classical sets are referred to as crisp sets in fuzzy set theory to differentiate them from
fuzzy sets. A crisp set C of the universe of discourse, or domain D, can be represented by using
its characteristic function 𝜇𝐶 :
The function 𝜇𝐶 : 𝐷 → [0,1] is a characteristic function of the set C if and only if for all d
in (7):
𝜇𝐶 (𝑑) = {

1 𝑖𝑓 𝑑 ∈ 𝐶
0 𝑖𝑓 𝑑 ∉ 𝐶

(7)

Therefore, for crisp sets every element of d either d ∈ C or d ∉ C. It is not the same for
fuzzy sets. Given a fuzzy set F, it is not necessary that d ∈ F, or d ∉ F. We can generalize this
function to a membership function that assigns every d ∈ C a value from the unit interval [0,1]
instead from the two element set {0,1}.
The membership function 𝜇𝐹 of a fuzzy set F is a function defined as 𝜇𝐹 : 𝐷 → [0,1].
Every element 𝑑 ∈ 𝐷 has a membership degree 𝜇𝐹 (𝑑) ∈ [0,1]. Thus, the fuzzy set F is
completely determined by (8):
𝐹 = {(𝑑, 𝜇𝐹 (𝑑)) | 𝑑 ∈ 𝐷}

(8)

where D and F are continuous domains, and 𝜇𝐹 is a continuous membership function. Figure 14
(a) and (b) shows the characteristic function of a crisp set and the membership function of a
fuzzy set respectively. Support of F denoted as supp(F) refers to the elements of D that have
degrees of membership to F.
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Crisp Set

µ

µ

Fuzzy Set

µC(d)

µF(d)

1

1

d

0

0
d1

Supp(F)=(d1, dn)

(a)

d2

d

(b)

Figure 14 The characteristic function of a crisp set (a) and the membership function
of a fuzzy set (b)
Throughout this document, only fuzzy sets with convex membership functions are
considered. A fuzzy set F is convex if and only if:
⋁𝑥, 𝑦 ∈ 𝑋⋁𝜆 ∈ [0,1]: 𝜇𝐴 (𝜆 ∙ 𝑥 + (1 − 𝜆) ∙ 𝑦) ≥ min(𝜇𝐴 (𝑥), 𝜇𝐴 (𝑦))
3.1.1 Fuzzy Inputs and Outputs
The FLC described here uses inputs and output variables whose states variables
are 𝑥1 , 𝑥2 , ⋯ , 𝑥𝑛 . Let X be a given closed interval of real numbers, a state variable 𝑥𝑖 with
values in the fuzzy sets are fuzzy state variables, and the set of these fuzzy values are called

term-set. The values 𝑥𝑖 are denoted as TXi, and the j − th value of the i − th fuzzy state is
denoted as LXij. Each LXij is defined by the membership function in (9):
LX ij = ∫ 𝜇𝑋 (𝑥)/𝑥

(9)

𝑋

where 𝜇𝑋 (𝑥)/𝑥 is the degree of membership of the crisp value 𝑥𝑖∗ of 𝑥𝑖 to the fuzzy value LXij of
𝑥𝑖 (Figure 15).
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µ
1

µLXij(x*i)

0

d

x*i

Figure 15 Degree of membership of the crisp value to the fuzzy value of the fuzzy
state variable
We refer to the fuzzy values LXij-1 and LXij+1 as the left and right neighbor of the fuzzy
value LXij respectively. Also, it is required that each fuzzy value shares a certain degree of
membership with its left and right neighbors:
1. supp(LXij−1 ) ∩ supp(LXij ) ≠ ∅
2. supp(LXij ) ∩ supp(LXij+1 ) ≠ ∅
3. 𝜇LXij−1 (𝑥) + 𝜇LXij (𝑥) = 1
4. 𝜇LXij (𝑥) + 𝜇LXij+1 (𝑥) = 1
3.1.2 The Fuzzy State Space
Given a fuzzy state vector 𝑥 = (𝑥1 , 𝑥2 , ⋯ , 𝑥𝑛 )𝑇 , each 𝑥𝑖 takes some fuzzy value LXi ∈ TXi.
Therefore, a random fuzzy state vector can be written as LX = (LX1, LX2, …, LXn)T. Each fuzzy
state variable takes its fuzzy values amongst the elements of a finite term-set; therefore, there
is a finite number of different fuzzy state vectors, denoted as LXi (for I = 1,2,…, M). The center
of a fuzzy region, LXi = (LX1i, LX2i, …, LXni)T defined by the crisp state vector 𝑥 𝑖 =
(𝑥1𝑖 , 𝑥2𝑖 , ⋯ , 𝑥𝑛𝑖 )𝑇 ∈ 𝑋 𝑛 , where 𝑥𝑘𝑖 are crisp values such that 𝜇LXij (𝑥1𝑖 ) = 1, 𝜇LXij (𝑥2𝑖 ) =
1, ⋯ , 𝜇LXij (𝑥𝑛𝑖 ) = 1.
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The general form of a model is given as 𝐱̇ = 𝐟(𝐱, 𝐮), where f is a 𝑛 × 1 state vector and
u is the 𝑛 × 1 input vector, and let 𝐮 = 𝐠(𝐱) be the control law. Then, we can estimate the
closed loop system as 𝐱̇ = 𝐟(𝐱, 𝐠(𝐱)).
3.2 Review of Related Literature
Fuzzy logic has proven to be a reliable method for approximate reasoning [84] since it
possess an easy user-interface and incorporates linguistic variables. In addition, fuzzy logicbased models can be used for non-linear, imprecise, complex systems by implementing human
experience, knowledge, and practice as a set of inference rules. However, fuzzy logic also
presents some challenges when dealing with decision making within probabilistic uncertainty,
and the automatic inclusion of fuzzy rules.
Fuzzy set theory effectively handles the deterministic uncertainty and subjective
information of clinical decision-making. Other decision-making approaches include neural
networks, utility theory, statistical pattern matching, decision trees, rule-based systems, and
model-based schemes. Fuzzy set theory has been successfully used alone or combined with
neural networks and expert systems to solve challenging biomedical problems in practice.
In machine learning, knowledge acquisition from examples (clinical patient data) is the
most common practical approach [91]. Other hybrid techniques have been used in the
literature dealing with multiple objectives and/or criteria. Some of these hybrid techniques are
expanded in the following paragraphs.
Fuzzy neural networks are popular due to relative ease of application. However, they
generally lack insight into the decision making process and similar levels of comprehensibility.
Fuzzy multi-objective decision-making (FMODM) where a fuzzy Pareto optimal solution set is
provided as a final solution [92], [93], is limited in that only some specific membership
functions (i.e. triangular distribution form) are used to deal with fuzzy parameters and fuzzy
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goals. Also, the values of objective functions are only described by crisp values, which is
sometimes not appropriate in practice since it would be preferred to deal with a range of values
for the objective function.
Fuzzy decision trees or fuzzy rule-based systems have the objective to induce decision
procedures with discriminative, descriptive, or taxonomic bias for classification of other samples
[91]. This follows the comprehensibility principle [94] which recommends that decision
procedures use language and mechanisms suitable for human interpretation and understanding.
Lastly, a fuzzy discrete event system approach to determining optimal treatment regimens was
developed by Ying et al, 2006 [90], in which an optimal treatment is selected after finding the
maximum possible agreement among a number of experts (physicians). However, this expert
system requires detailed knowledge from a group of experts and cannot be generalized.
Although fuzzy inference systems have been applied in many engineering fields, they
have not been extensively applied for medical decision modeling. Models like Bayesian Decision
Theory/models are appropriate for groups of patients but are complicated in application to
individual patient factors.
The proposed method in this research tackles limitations currently found in the fuzzybased models. They include (1) Decision flexibility: compared to current fuzzy rule-based
models, the decision process can be dynamic, allowing the decision maker to change priorities
for the rule after learning about the set of options; thus, the patient’s preferences can be
represented as priorities in the expert system. (2) Uncertainty: referring to the imprecision
inherent in human judgments, probabilistic characteristics may be incorporated in some
parameters of the decision model.
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3.3 Objectives
·

Objective 1: Develop an expert decision knowledge-based system that effectively depicts
patient preferences and evaluate rectal cancer treatment options

·

Objective 2: Integrate patient-centered measures into a decision model that considers
multiple criteria

3.4 Hypotheses
·

Decision procedures implemented in the model can use language and mechanisms
suitable for human interpretation and understanding

·

The physician and the patient can jointly use these models to compare alternative
medical interventions and make a decision on choosing the most appropriate
intervention for the patient.

·

The decision model is capable of incorporating weights to prioritize conflictive objectives
for the treatment outcomes. The decision framework allows decision makers to modify
priorities for the various criteria/objectives considered to make the selection of
treatments.

3.5 Fuzzy Inference System Approach
The FDSM developed in this work is applicable for the diagnostic phase in which the
current or future state of a person’s health status is inexact and treatment options are generally
subject to predetermined clinical pathways and medical expertise. Subjective human decision
making (physician’s or patient’s) play a significant role in defining the status of state. The status
mostly likely is not crisp and neither is the transition from one state to another [90]. An
appropriate representation of the inherent subjectivity and uncertainty in fields like medicine
and treatment selection is provided by the fuzzy inference system theory.
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The decision inputs used for the decision model are acquired using retrospective data
analysis. The description of the data used and the process of rule mining are presented in
section 3.5.4. The model results present the treatment of choice for stage II and stage III (no
metastasis) rectal cancer patients that have not received treatment before. Three treatment
regimens are considered as alternatives for the patient:
1. Surgery alone (S)
2. Radiation and Surgery, either neoadjuvant and adjuvant (RS)
3. Observation/No treatment (NT)
Decision making in cancer treatment is generally performed by the physician who will
recommend a treatment based on his/her expertise. Considerations include weighting several
factors to increase patient chances of survival while minimizing potential adverse effects. The
essential elements of an effective cancer treatment regimen include:
1. Minimizing treatment toxicity and adverse effects -- this is measured in terms of toxicity
of the treatment.
2. Selecting a treatment that can cure or eliminate the cancer tumor -- this is measured in
terms of the 5 yr. Survival rate of the patient.
3. Selecting a treatment sufficiently intense increase chances of survival and reduces rate
of recurrence -- this is measured in terms of radiosensitivity.
A prediction model for radiation sensitivity has been developed by Torres-Roca [15],
[35] using a gene expression classifier. Since this gene classifier is not currently being used in
practice, and no data is available, we will estimate the impact of this factor using a sensitivity
analysis. The theoretical framework adopted for the fuzzy logic implemented here was
developed by Dr. Hao Ying at al. [90]. We have expanded this methodology by the inclusion of
patient preference in the decision making process and a data driven expertise acquisition
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method using predictive models and clinical trials results. This study does not use the estimated
clinical features intrinsic to historical treatment regimens; instead, it personalizes theses
estimates using patient’s characteristics. The overall methodology of this decision framework is
summarized in Figure 16.

Fuzzy Inference System
Estimation of clinical
parameters

Age
Gender
Cancer Stage
Grade
Gene expression profile
...

Definition of
membership
functions

Transition
matrices and
state vectors
estimation

Survival:
Low – Medium - High
Adverse events:
Minor – Moderate - Major
Efficacy:
Unlikely – Neutral - Likely

Preference
function E(h)
measure
(Dezzifucation)

E(h) for Treatment 1

E(h) for Treatment i

Weight vectors for
survival (WS )
Adverse events (WA)
Efficacy (WE)

Figure 16 Fuzzy inference system approach
3.5.1 State Transitions Matrices
The treatment selection as presented in Table 6 is made considering three criteria:
cause-specific survival rate (survivability), adverse events and efficacy.
The three clinical parameters have been chosen for treatment selection (other
parameters can be considered, but are not in the scope of this work), and each parameter has
three levels. Three fuzzy state vectors, denoted as q1, q2, and q3 represent the state of
survivability, adverse effects, and efficacy respectively. Survivability state vector q1 has four
components: initial, low, medium, and high, and it is a 1 × 4 vector with the initial state being
represented by [1 0 0 0]. Adverse events state vector q2 has four components first, second, and
third grade, and it is a 1 × 4 vector with the initial state being represented by [1 0 0 0]. Lastly,
efficacy state vector q3 has four components unlikely, neutral, and likely, and it is 1 × 4 vector
with the initial state being represented by [1 0 0 0]. Therefore, if q3 = [0 0 0.2 0.8], it means
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that the treatment is in a state with membership of 0.2 for neutral efficacy and 0.8 for likely
efficacy. The model has 27 possible combinations (3x3x3=27) and 9 transition matrices for the
3 regimens.
Table 6 Decision model elements and membership functions

Decision Criteria

Category

Membership Function

Low
Cause-specific
Survival rate

{

{

1st grade

{

{

1 𝑥−85 2
− (
)
𝑒 2 5
1 𝑥−20
− (
)
𝑒 2 5

Likely

{

45

, −∞<𝑥 <∞

1, 𝑥 > 45
1 𝑥−45 2
− (
)
𝑒 2 5
1 𝑥−45
− (
)
2 5

, 𝑥 ≤ 45

2

, 𝑥 > 45
1, 𝑥 ≤ 45

1 𝑥−65 2
− (
)
𝑒 2 6

Neutral

, 𝑥 ≤ 85

2

, 𝑥 > 20
1, 𝑥 ≤ 20

{𝑒

unlikely

, −∞<𝑥 <∞

1, 𝑥 > 85

1 𝑥−30 2
− (
)
𝑒 2 6

2nd grade

3rd grade

Efficacy

, 𝑥 > 55
1, 𝑥 ≤ 55

1 𝑥−55 2
− (
)
𝑒 2 6

Medium

High

Adverse events

1 𝑥−55 2
− (
)
𝑒 2 5

, −∞<𝑥 <∞

1, 𝑥 > 85
1 𝑥−85 2
− (
)
𝑒 2 5

, 𝑥 ≤ 85

Figure 17 Membership functions in terms of survival, adverse events and efficacy
3.5.2 Membership Functions
Semi-Gaussian functions are used to produce gradual changes of membership (Table 6)
and have been empirically defined based on the parameters of the data used (SEER databases)
and clinical trials for survival, adverse effects (toxicity) and efficacy. These constraints are
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tunable to the discretion of the analyst/decision maker. The memberships functions levels and
constrains are shown in Figure 17.
3.5.3 Input Data
The Surveillance, Epidemiology, and End Results (SEER) database was used for our
model survival calculations and analysis. According to the National Cancer Institute: ”The SEER
Program registries routinely collect data on patient demographics, primary tumor site, tumor
morphology and stage at diagnosis, first course of treatment, and follow-up for vital status. The
SEER Program is the only comprehensive source of population-based information in the United
States that includes stage of cancer at the time of diagnosis and patient survival data.” A signed
research data agreement was approved to access these data and is included in appendix C. The
variables available in this database are included in appendix D.
The data processing steps to obtain the patient cohort used in the analysis is presented
in Figure 18. The demographic, tumor/cancer stage statistics and treatment options are
presented in table 7, 8 and 9 respectively.

SEER RESEARCH DATA
CASES DIAGNOSED 2000-2010

7,732,511 Cases

Colorectal Cases

238,665 Cases

Cases from 2004 to 2010
New Staging System

148,948 Cases

Sample by stage of cancer II and
III

36,088 Cases

Figure 18 Pre-modeling and knowledge extraction data processing steps
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Table 7 Patient cohort descriptive statistics
Patient characteristics
Gender
Male
Female
Race
White
Black
Other (American Indian/AK Native, Asian/Pacific
Islander)
Unknown
Marital Status
Married (including common law)
Single (never married)
Widowed
Divorced
Unknown
Separated
Age
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
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n

%

18442 51.1
17646 48.9
30198 83.68
4173
11.56
1595

4.42

122

0.34

19588
4504
7110
3151
1346
389

54.28
12.48
19.7
8.73
3.73
1.08

1
17
47
112
262
515
977
1890
2905
3451
3991
4433
4553
4648
4230
4056

0
0.05
0.13
0.31
0.73
1.43
2.71
5.24
8.05
9.56
11.06
12.28
12.62
12.88
11.72
11.24

Table 8 Cancer and tumor stage statistics
Cancer State
n
%
Derived AJCC Stage Group, 6th ed (2004+)
Stage IIA
15346 42.52
Stage IIB
2588
7.17
Stage IIIA
2247
6.23
Stage IIIB
9560 26.49
Stage IIIC
6284 17.41
Stage III NOS
63
0.17
Grade
I
2409
6.68
II
24603 68.18
III
6917 19.17
IV
815
2.26
Cell type not determined
1344
3.72

Table 9 Treatment options
Treatment
Procedure
No treatment (not recommended or refused)
Surgery
Radiation and Surgery (neoadjuvant or adjuvant)
Radiation alone
Reporting Source
Hospital inpatient
Radiation Treatment Centers or Medical Oncology
Centers
Laboratory Only (hospital-affiliated or independent)
Physician’s Office/Private Medical Practitioner (LMD)
Nursing/Convalescent Home/Hospice
Other hospital outpatient units/surgery centers
Insurance type
Insured
Any Medicaid
Uninsured
Insurance status unknown
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n

%

551
1.53
29872 82.78
5220 14.47
445
1.23
35432 98.18
120

0.33

211
176
1
148

0.58
0.49
0
0.41

30540 84.63
3434
9.52
1355
3.75
759
2.1

Cause-specific survival (DTH_CLASS variable in SEER database) was used as the
dependent variable for the development of a logistic regression model. This variable designates
if the person died of cancer for cause-specific survival. DTH_CLASS = 1 if alive or dead due to
other causes, and DTH_CLASS = 0 if dead due to colorectal cancer. The dataset was split into
an 80% training data and 20% validation data. A stepwise process was performed to select the
variables in the model (0.05 significant level for entry and exit at each step). All final variables
are significant in the model as presented in Table 10. Performance was measured in terms of
the area under the curve (auc) for training and validation data (auc= 0.741 in the training data
and 0.71 in the validation data). The values for the parameter estimates are included in the
appendix E.
Table 10 Logistic regression chi-square values for selected variables
Type 3 Analysis of Effects
Effect

DF

Wald Pr > ChiSq
Chi-Square

Treatment type

2

199.6288

<.0001

Marital Status

5

48.2899

<.0001

Race

3

39.7533

<.0001

Gender

1

13.3585

0.0003

15

643.4756

<.0001

AJCC Stage

5

854.2814

<.0001

Grade

4

152.7802

<.0001

Insurance

3

48.8115

<.0001

Age

Results from the logistic regression suggest that higher chances of survival are
associated with treatments where radiation and surgery are combined (either neoadjuvant or
adjuvant), compared to surgery alone. However, patients receiving no treatment were 4.76
times more likely of no surviving than receiving surgery alone. Women were 1.16 more likely to
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survive than men. Patients in cancer stages 2B, 3B and 3C has the least chances of survival
compared to patient in earlier stages. Finally, cancer tumor with grades 3 and 4 were 0.6 times
more likely to be associated with higher survival rates. Odds ration estimates are presented in
Table 11.
Table 11 Odds ratio estimates for logistic regression
Odds Ratio Estimates
Effect

Point Estimate

Treatment: Observation vs Surgery

0.211

Treatment: Radiation/surgery vs
Surgery

1.05

Gender: F vs M

1.16

Stage: D_AJCC_S 2B vs 2A

0.333

Stage: D_AJCC_S 3A vs 2A

0.934

Stage: D_AJCC_S 3B vs 2A

0.425

Stage: D_AJCC_S 3C vs 2A

0.233

Stage: D_AJCC_S 3N vs 2A

0.483

Grade: 2 vs 1

0.997

Grade: 3 vs 1

0.597

Grade: 4 vs 1

0.589

Grade: N vs 1

0.69

Insurance: Medicaid vs Insured

0.677

Insurance: Uninsured vs Insured

0.843

Insurance: Unknown vs Insured

1.301

In this study adverse events are measured by the Toxicity. According to the NCI,
Toxicity grade ranges from one to five, where 1 = Mild, with no or mild symptoms; no
interventions required; 2 = Moderate side-effects; 3 = Severe but not life-threatening;
limitation of patient's ability to care for him/herself; 4 = Life Threatening or Disabling side51

effects; 5 = Death related to adverse event. For example, the acute morbidity criteria used to
grade toxicity from radiation therapy in the gastro-intestinal area is included in Table 12.
Table 12 Criteria used to grade toxicity from radiation therapy. Content from the
RTOG Acute Radiation Morbidity Scoring Criteria.
1

Lower
gastrointestinal.

No
change

2

· Increased
frequency or
change in quality
of bowel habits
not requiring
medication
· Rectal discomfort
not requiring
analgesics

3

· Diarrhea requiring
parasympatholytic
drugs
· Mucous discharge
not necessitating
sanitary pads
· Rectal or abdominal
pain requiring
analgesics

4

5

· Diarrhea
requiring
parenteral
support
· Severe mucous or
blood discharge
necessitating
sanitary bags
· Abdominal
distention

· Acute or
subacute
obstruction,
fistula or
perforation
· GI bleeding
requiring
transfusion
· Abdominal pain
or tenesmus
requiring tube
decompression
or bowel
diversion

Given any given patient, whose clinical characteristics and predicted outcomes per
treatment have been estimated based on their individual characteristics, the transition matrices
are calculated using the membership functions defined. For example, consider the case where
the estimated/predicted clinical outcomes of one patient are given as shown in Table 13. The
transition matrices are calculated by determining the degree of membership of the clinical
parameters for survivability, adverse events and efficacy. For the example, the transition
matrices for survivability and the three treatment options are given in Table 14.
The probabilities of transferring from the initial state (no previous cancer treatment) to
the medium and high survivability state are 0.839 and 0.161 respectively (Table 14). This study
does not consider patients that were previously treated for cancer, otherwise the low, medium
and high row would contain non-zero probabilities. The other six transition probabilities are
estimated in the same way and can be found in appendix F.
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The state factors are calculated for the initial state after the first round of surgery:
[max(0,0,0,0) max(0.839,0,0,0) max(0.161,0,0,0)] = [0 0.839 0.161]. Thus, the patient state
after surgery is in 0.839 in a “medium survivability” state and 0.0161 in a “high survivability”
state. The state vectors for all treatment options and clinical parameters are given in Table 15.
Table 13 Example of predicted patient clinical parameters
Survivability

Adverse Events

Efficacy

Option 1

Surgery alone

75

30

60

Option 2

Radiation and Surgery

85

40

70

Option 3

Observation

50

10

10

Table 14 Survival transition matrices

Surgery alone

Radiation and Surgery

Observation

initial

low

med

high

0

0.000

0.839

0.161

0

0

0

0

low

0

0

0

0

med

0

0

0

0

high

initial

low

med

high

0

0.000

0.042

0.958

0

0

0

0

low

0

0

0

0

med

0

0

0

0

high

initial

low

med

high

0

0.994

0.004

0.000

0

0

0

0

low

0

0

0

0

med

0

0

0

0

high
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initial

initial

initial

Table 15 State vectors for all treatment options and clinical parameters
Survivability
initial

low

med

high

Surgery alone

0.0000000

0.0003983

0.8389319

0.1606699

Radiation and Surgery

0.0000000

0.0000000

0.0420877

0.9579123

Observation

0.0000000

0.9936665

0.0037032

0.0000000

initial

Minor

Moderate

Major

Surgery alone

0.0000000

0.1180479

0.8722622

0.0096900

Radiation and Surgery

0.0000000

0.0003918

0.2912250

0.7083832

Observation

0.0000000

0.9722278

0.0277722

0.0000000

initial

unlikely

neutral

likely

Surgery alone

0.0000000

0.0154773

0.9845175

0.0000052

Radiation and Surgery

0.0000000

0.0000052

0.9845175

0.0154773

Observation

0.0000000

1.0000000

0.0000000

0.0000000

Adverse events

Efficacy

3.5.4 Measure of Preference
A measure of preference needs to be created for the patient or the physician to compare
and select from different regimens. The function, E(h) in equation (10), is defined as the
weighted average of the new state vectors:
𝐸(ℎ) = 𝛼 ∙ 𝑊𝑆 + 𝛽 ∙ 𝑊𝐴 + 𝛾 ∙ 𝑊𝐸

(10)

where 𝑊𝑆 , 𝑊𝐴 and 𝑊𝐸 are the weight vectors for survival, adverse effects and treatment
efficacy. The decision maker will assign a weight factor to each clinical parameter, and based on
their clinical profile, the treatment with the highest 𝐸(ℎ) will be selected. Consider the
preference scenarios on Table 16 for the case given in Table 13. For instance, given the state
vectors from Table 15 and preference weights in Table 16, 𝐸(ℎ) for scenario 4 and surgery as
treatment option is calculated as follows:
𝐸(ℎ) = [ 0 0 0.839 0.161][0 0.2 0.6 0.1]𝑇 + [0 0.118 0.872 0.010 ][0 1 0 0 ]𝑇
+ [ 0 0.015 0.985 0][0 0.2 0.6 0.1]𝑇 = 0.279
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Table 16 Simulation of various preference scenarios
Scenario

1

2

3

4

𝑾𝑺

[0001]

[0001]

[0001]

[ 0 0.25 0.6 0.15]

𝑾𝑨

𝑾𝑬

[0100]

[0001]

[0100]

[ 0 0 0.5 0.5 ]

[ 0 0.5 0.5 0 ]

[0001]

[0100]

[ 0 0.25 0.6 0.15]

Decision preference and
description
Ideal scenario: all weight
assigned to high survival,
having minor adverse
effects, and likely treatment
efficacy.
All weight assigned to high
survival, having minor
adverse effects, and equal
preference on neutral and
likely treatment efficacy.
All weight assigned to high
survival, having same
preference on minor or
moderate adverse effects,
but likely treatment efficacy.
Determining treatment
decision for a patient
preferring to have the least
adverse effects, and medium
to high survival, and neutral
to likely treatment efficacy.

The preference measure is similarly calculated for all treatment options and results are
presented in Figure 19.
The results obtained in Figure 19 are dependent on the clinical parameters of the patient
used as example (Table 13), given a different patient with the same preferences levels, these
results will differ depending on the predisposition to treatment success of each patient.
In scenario 1, the two preferred treatment options are radiation plus surgery or
observation (no treatment). This is a result of the patient’s 100% preference of choosing a
treatment with minor adverse effects, therefore a high level of preference to not perform any
treatment. However, radiation and surgery have a slightly higher preference level since the
patient also chose to have a treatment with high chances of survival and likely treatment
efficacy.
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Measure of Preference for Four scenarios
3.5

3.0

E(h)

2.5

2.0

1.5

1.0

0.5

0.0

1

2

3

4

Observation

0.972

0.972

0.500

1.373

Radiation and Surgery

0.974

1.458

1.119

0.714

Surgery alone

0.279

0.771

0.656

1.231

Figure 19 Results of simulation of various preference profiles
In scenario 2 and 3, radiation and surgery are selected as the preferred treatment
options. This is the result of having a high preference of a treatment that has high survival
chances, minor to moderate adverse effects and neutral to likely efficacy.
In scenario 4, observation was chosen as the treatment choice for a patient that
strongly prefers a treatment with minor adverse effects, moderate survival chances and
treatment efficacy.
Other scenarios and treatment selections based on minor adverse effects and maximum
survival are presented in Figure 20 and Figure 21.
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Surgery alone

57

Radiation and Surgery

Figure 21 Sensitivity analysis based for efficacy

Observation
[0100]

[ 0 0.9 0.1 0 ]

[ 0 0.8 0.2 0 ]

Radiation and Surgery

[ 0 0.7 0.3 0 ]

[ 0 0.6 0.4 0 ]

[0010]

[ 0 0.1 0.9 0 ]

[ 0 0.2 0.8 0 ]

[ 0 0.3 0.7 0 ]

[ 0 0.4 0.6 0 ]

Surgery alone

[ 0 0.5 0.5 0 ]

[ 0 0 0.5 0.5 ]

[ 0 0 0.4 0.6 ]

[ 0 0 0.3 0.7 ]

[ 0 0 0.2 0.8 ]

[ 0 0 0.1 0.9 ]

[0001]

E(h)

[0100]

[ 0 0.9 0.1 0 ]

[ 0 0.8 0.2 0 ]

[ 0 0.7 0.3 0 ]

[ 0 0.6 0.4 0 ]

[0010]

[ 0 0.1 0.9 0 ]

[ 0 0.2 0.8 0 ]

[ 0 0.3 0.7 0 ]

[ 0 0.4 0.6 0 ]

[ 0 0.5 0.5 0 ]

[ 0 0 0.5 0.5 ]

[ 0 0 0.4 0.6 ]

[ 0 0 0.3 0.7 ]

[ 0 0 0.2 0.8 ]

[ 0 0 0.1 0.9 ]

[0001]

E(h)
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
Decision based on minor adverse effects: WA=[0 1 0 0]

Observation

Figure 20 Sensitivity analysis based for survival
Decision based on maximun surivival: WS=[0 0 0 1]

4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0

3.5.5 Sensitivity Analysis for Radiosensitivity
One of the main objectives of this work is to assess the inclusion of treatment efficacy in
terms of radiosensitivity (chapter 2). For this assessment, a sensitivity analysis was conducted
to evaluate the treatment selection change when this criterion is included in the decision
making process. As treatment efficacy can have values from 0 to 100. A value of 0 represents a
patient that is completely radio-resistant (therefore resistant to radiation treatment), and a
value of 100 a patient is completely radiosensitive (therefore sensitive to radiation treatment).
For the example in this chapter, the analysis consisted on determining the treatment
selected when the treatment efficacy (radiosensitivity) increased from 0 to 100. Results are
presented in Figure 22 (1: surgery; 2: radiation and surgery; and 3: observation).

Figure 22 Sensitivity analysis for various treatment efficacy levels
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3.6 Discussion
This study contributes to the arena of patient centered decision-making, using
knowledge extracted from available data to guide patient and physician treatment selection.
Although the expertise used in this model is acquired from current cancer practices in the
United States and historical data over 6 years, the decision models need to be updated to
reflect current values for cause-specific survival rate and toxicity. Knowledge is extracted from
clinical trials results for toxicity for various treatments, and from the SEER data (2004-2010)
from the National Cancer Institute to predict the patient cause-specific survival rate. A limitation
for this study is the inclusion/updating the expertise. The updating of decision rules and other
parameters can represent a complete redesign of the entire system.
Decision making is normally physician-dependent, and this study explores the inclusion
of patient preferences in the decision making process. This can be of value moving forward the
initiatives to make the patient the center of all process improvement and practices in the
healthcare environment (PCORI mission).
At the time when this dissertation was written, radiosensitivity still has not been
implemented in current medical practices, therefore, the sensitivity analysis performed to
evaluate the impact of this clinical parameter is innovative and valuable. Current efforts are
being made to make radiation sensitivity (radiosensitivity) to be part of current oncology
practices. This would be of great benefit to better guide and customize treatment selection to
each patient’s individual characteristics. As it was presented in Figure 22, the selection of
treatment was significantly influenced by this information. Based on the case given, radiation
combined with surgery was only the preferred treatment choice when the value for radiation
sensitivity was over 70%.
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CHAPTER 4: CONCLUSIONS AND FUTURE RESEARCH
This research is relevant to the continuously evolving area of personalized medicine,
specifically by:
·

Developing decision models that allow patients to assess alternative options for
treatment and make informed decisions based on their preferences and characteristics

·

Advancing fundamental understanding of cancer biology and clinical oncology that can
promote the prevention, detection, and treatment of cancer diseases
Genomic patient data although existent, it is rarely used in clinical settings for real-life

patient care [34]. However, given the research interest and on-going research growth
associated to this area, it is necessary to develop decisions models that consider individual
genomic information and that are ready for adoption and transition once this information
becomes readily available.
Based on the current limitations that found applicable to fuzzy decision frameworks, this
research can potentially be of transformative nature. Specifically the intellectual merit can be
summarized as follows:
1. Interdisciplinary research by integrating concepts from the fields of artificial intelligence,
medicine, biology, biostatistics, economics, and mathematical programming to develop a
decision aid approach whose solution are beyond the scope of a single area of research
practice, and with an expected high practical value
2. Solution approach that is specific to modeling doctor’s expertise and human preferences
in the evaluation of alternatives
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3. The model integrated criteria is relevant to cancer treatment selection, but it can be
applicable to other scenarios where conflictive objectives are being considered
4. Comprehensibility principle: the decision model allows the use of language and
mechanisms suitable for human interpretation and understanding. The fuzzy component
allows us to capture concepts with graduated characteristics
4.1 Conclusions
This study provides clinical support for a practical and novel assay to predict tumor
radiosensitivity. Due to the difference in experimental measurement in DNA microarray gene
expression values among different cohorts, calibration methods should be created to
standardize validation across different sites. Further testing of this technology in larger clinical
populations is supported.
The proposed method in this research approaches limitations currently found in the
fuzzy-based models: (1) Decision flexibility: compared to current fuzzy rule-based models, the
decision process for this approach can be dynamic, allowing the decision maker to change
priorities for the rule and be presented with a set of options; thus, the patient’s preferences can
be represented as priorities in the expert system. (2) Uncertainty: referring to the imprecision
inherent in human judgments, uncertainty may be incorporated in some parameters of decision
model.
4.2 Future Research
The predictive models developed in this research are predicting radiosensitivity with
acceptable performance. These models are also capable to discriminating between responders
and non-responders when the models were validated against clinical data. However, a random
forests model is considered a black box machine learning algorithm. This work will continue on
exploring methods that can help us understand the patterns in the algorithm of how genes
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interact with each other. This can be achieved by the use of sensitivity analysis that will
“unmask” the functions that associate the input variables with the response variables (which is
the case for random forest, support vector machines and neural networks).
The fuzzy decision framework presented in this research only considers patients that
have not received cancer treatment before, but it can expanded to patients in other treatment
states (e.g. after radiation therapy or patients with recurring cancers) where decision-making is
more complex. Also, the decision model would benefit of further research in the clinical
parameters used as input in the models; especially for adverse effects (as an indicator of quality
of life). Finally, the decision models should also include confidence intervals for the clinical
parameters to account for the uncertainty of the clinical estimates used.
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Appendix A Rectal Cancer Detection and Staging
Risk Factors
[age] Being aged 40 or older.
[Genetics]
- Having certain hereditary conditions, such as familial adenomatous polyposis (FAP) and
hereditary nonpolyposis colon cancer (HNPCC or Lynch syndrome).
- Having a parent, brother, sister, or child with a history of colorectal cancer or polyps.
- Having a personal history of any of the following: colorectal cancer; Polyps (small pieces of
bulging tissue) in the colon or rectum; Cancer of the ovary, endometrium, or breast.

Rectal Cancer
Detection and
Staging
detect and
diagnose rectal
cancer.

Staging

prognosis and
treatment
options

Stage 0

Physical exam and history
Digital rectal exam (DRE)
Proctoscopy
Colonoscopy
Biopsy
Reverse-transcription polymerase chain reaction (RT-PCR) test
Immunohistochemistry study
Carcinoembryonic antigen (CEA) assay s
Chest x-ray
CT scan (CAT scan)
MRI (magnetic resonance imaging)
Endoscopic ultrasound (EUS)
Carcinoembryonic antigen (CEA) assay
PET scan (positron emission tomography scan)
The stage of the cancer (whether it affects the inner lining of the rectum only, involves the whole rectum,
or has spread to lymph nodes, nearby organs, or other places in the body).
- Whether the tumor has spread into or through the bowel wall.
- Where the cancer is found in the rectum.
- Whether the bowel is blocked or has a hole in it.
- Whether all of the tumor can be removed by surgery.
- The patient’s general health.
- Whether the cancer has just been diagnosed or has recurred (come back).

abnormal cells are found in the mucosa (innermost layer) of the rectum wall. These abnormal
cells may become cancer and spread. Stage 0 is also called carcinoma in situ.

Stage I

cancer has formed in the mucosa (innermost layer) of the rectum wall and has spread to the submucosa
(layer of tissue under the mucosa). Cancer may have spread to the muscle layer of the rectum wall.

Stage II

Stage IIA: Cancer has spread through the muscle layer of the rectum wall to the serosa (outermost layer) of the rectum wall.
Stage IIB: Cancer has spread through the serosa (outermost layer) of the rectum wall but has not spread to nearby organs.
Stage IIC: Cancer has spread through the serosa (outermost layer) of the rectum wall to nearby organs.

Stage III

In stage IIIA: Cancer may have spread through the mucosa (innermost layer) of the rectum wall to the submucosa (layer of tissue under
the mucosa) and may have spread to the muscle layer of the rectum wall. Cancer has spread to at least one but not more than 3 nearby
lymph nodes or cancer cells have formed in tissues near the lymph nodes; or Cancer has spread through the mucosa (innermost layer) of
the rectum wall to the submucosa (layer of tissue under the mucosa). Cancer has spread to at least 4 but not more than 6 nearby lymph
nodes.
In stage IIIB: Cancer has spread through the muscle layer of the rectum wall to the serosa (outermost layer) of the rectum wall or has
spread through the serosa but not to nearby organs. Cancer has spread to at least one but not more than 3 nearby lymph nodes or cancer
cells have formed in tissues near the lymph nodes; or Cancer has spread to the muscle layer of the rectum wall or to the serosa (outermost
layer) of the rectum wall. Cancer has spread to at least 4 but not more than 6 nearby lymph nodes; or Cancer has spread through the
mucosa (innermost layer) of the rectum wall to the submucosa (layer of tissue under the mucosa) and may have spread to the muscle
layer of the rectum wall. Cancer has spread to 7 or more nearby lymph nodes.
In stage IIIC: Cancer has spread through the serosa (outermost layer) of the rectum wall but has not spread to nearby organs. Cancer has
spread to at least 4 but not more than 6 nearby lymph nodes; or
Cancer has spread through the muscle layer of the rectum wall to the serosa (outermost layer) of the rectum wall or has spread through
the serosa but has not spread to nearby organs. Cancer has spread to 7 or more nearby lymph nodes; or
Cancer has spread through the serosa (outermost layer) of the rectum wall and has spread to nearby organs. Cancer has spread to one or
more nearby lymph nodes or cancer cells have formed in tissues near the lymph nodes.

Stage IV

Stage IVA: Cancer may have spread through the rectum wall and may have spread to nearby organs or lymph nodes. Cancer has spread to one
organ that is not near the rectum, such as the liver, lung, or ovary, or to a distant lymph node.
Stage IVB: Cancer may have spread through the rectum wall and may have spread to nearby organs or lymph nodes. Cancer has spread to
more than one organ that is not near the rectum or into the lining of the abdominal wall.

Figure A.1 Rectal cancer detection and staging
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Appendix B Figure Permission
Permission to use figure 1 was provided by Terese Winslow.
terese.winslow@mindspring.com to use in this dissertation on May 17/2014

I have created all other figures for this manuscript, and no other material is being used
or published elsewhere.
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Appendix C SEER Data Use Agreement
The data use agreement was approved on Feb 5, 2014.
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Appendix D SEER Database Variables Used
Table D.1 SEER database variables used
VARIABLE NAME
CS_SSF25
D_AJCC_T
D_AJCC_N
D_AJCC_M
D_AJCC_S
CS0204SCHEMA
CASENUM
REG
MAR_STAT
RACE
NHIA
SEX
AGE_DX
SEQ_NUM
DATE_mo
DATE_yr
SITEO2V
HISTO2V
BEHO2V
HISTO3V
BEHO3V
GRADE
REPT_SRC
REC_NO
AGE_REC
HISTREC
BRAINREC
NUMPRIMS
SRV_TIME_MON
SRV_TIME_MON_FLAG
INSREC_PUB
RAC_RECA
RAC_RECY
NHIAREC
CS_SIZE
CS_EXT
CS_NODE
CS_METS
SURGPRIM
SURGNODE
NO_SURG
RADIATN
RAD_SURG
SCOPE
SURGOTH

VARIABLE DESCRIPTION
CS Site-Specific Factor 25
Derived AJCC T
Derived AJCC N
Derived AJCC M
Derived AJCC Stage Group
CS Schema v0204
Patient ID number
Registry ID
Marital Status at DX
Race/Ethnicity
NHIA Derived Hispanic Origin
Sex
Age at diagnosis
Sequence Number--Central
Month of diagnosis
Year of diagnosis
Primary site
Histology (92-00) ICD-O-2
Behavior (92-00) ICD-O-2
Histologic Type ICD-O-3
Behavior Code ICD-O-3
Grade
Type of Reporting Source
SEER Record number
Age Recode <1 Year olds
Histology Recode--Broad Groupings
Histology Recode--Brain Groupings
Number of primaries
Survival months
Survival months flag
Insurance Recode (2007+)
Race recode (White, Black, Other)
Race recode (W, B, AI, API
Origin Recode NHIA(Hispanic,Non-Hisp)
CS Tumor size (from 2004)
CS Extension
CS Lymph Nodes
CS Mets at DX
RX Summ--Surg Prim Site
RX Summ--Reg LN Examined
Reason for no surgery
RX Summ--Radiation
RX Summ--Surg/Rad Seq
RX Summ--Scope Reg LN Sur
RX Summ--Surg Oth Reg/Dis
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Appendix E Parameter Estimates for the Logistic Regression
Table E.1 Parameter estimates for the logistic regression
Parameter

DF

Estimate

Standard Error

Wald Chi-Square

Pr > Ch-sqChiSq

Intercept

1

2.3291

10.1799

0.0523

0.819

TREATment

No

1

-1.0536

0.0749

197.765

<.0001

TREATment

RS

1

0.551

0.0505

118.921

<.0001

MAR_STAT

D

1

-0.1059

0.0661

2.5677

0.1091

MAR_STAT

E

1

0.2827

0.1703

2.7575

0.0968

MAR_STAT

M

1

0.1253

0.0478

6.8685

0.0088

MAR_STAT

S

1

-0.1908

0.059

10.4572

0.0012

MAR_STAT

W

1

-0.1511

0.0544

7.6988

0.0055

RAC_RECA

B

1

-0.4475

0.1102

16.5006

<.0001

RAC_RECA

O

1

0.0137

0.1226

0.0125

0.9111

RAC_RECA

U

1

0.5526

0.3014

3.3617

0.0667

SEX

F

1

0.0742

0.0203

13.3585

0.0003

AGE_REC

3

1

6.0071

152.7

0.0015

0.9686

AGE_REC

4

1

0.5897

10.2268

0.0033

0.954

AGE_REC

5

1

0.2508

10.1917

0.0006

0.9804

AGE_REC

6

1

-0.0172

10.1853

0

0.9987

AGE_REC

7

1

0.0268

10.1821

0

0.9979

AGE_REC

8

1

-0.2733

10.1804

0.0007

0.9786

AGE_REC

9

1

0.0385

10.1801

0

0.997

AGE_REC

10

1

-0.1542

10.1796

0.0002

0.9879

AGE_REC

11

1

0.0351

10.1795

0

0.9972

AGE_REC

12

1

-0.3029

10.1794

0.0009

0.9763

AGE_REC

13

1

-0.5177

10.1794

0.0026

0.9594

AGE_REC

14

1

-0.5622

10.1794

0.003

0.956

AGE_REC

15

1

-0.8548

10.1794

0.0071

0.9331

AGE_REC

16

1

-1.1174

10.1794

0.012

0.9126

AGE_REC

17

1

-1.3787

10.1794

0.0183

0.8923

D_AJCC_S

2A

1

0.7012

0.0727

93.1459

<.0001

D_AJCC_S

2B

1

-0.3976

0.0806

24.34

<.0001

D_AJCC_S

3A

1

0.6333

0.1062

35.5295

<.0001

D_AJCC_S

3B

1

-0.1534

0.0714

4.6129

0.0317

D_AJCC_S

3C

1

-0.7567

0.0725

109.074

<.0001

GRADE

1

1

0.2838

0.072

15.5262

<.0001

GRADE

2

1

0.2804

0.0387

52.5588

<.0001

GRADE

3

1

-0.2316

0.0441

27.6239

<.0001

GRADE

4

1

-0.2451

0.0889

7.6087

0.0058

INSREC_PUB

I

1

0.0743

0.0503

2.1852

0.1393

INSREC_PUB

M

1

-0.3154

0.0605

27.1385

<.0001

INSREC_PUB

U

1

-0.096

0.0853

1.2668

0.2604
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Appendix F Transition Probabilities for Adverse Effects and Efficacy
Table F.1 Transition probabilities for adverse effects and efficacy
Adverse Effects
Surgery alone
Radiation and Surgery
Observation

Surgery alone

Radiation and Surgery

Observation

Treatment Efficacy
Surgery alone
Radiation and Surgery
Observation

Surgery alone

Radiation and Surgery

Observation

30
40
10
initial
0
0
0
0
initial
0
0
0
0
initial
0
0
0
0
60
70
10
initial
0
0
0
0
initial
0
0
0
0
initial
0
0
0
0

Minor
0.118
0
0
0
Minor
0.000
0
0
0
Minor
0.972
0
0
0

low
0.015
0
0
0
unlikely
0.000
0
0
0
unlikely
1.000
0
0
0
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Moderate
0.872
0
0
0
Moderate
0.291
0
0
0
Moderate
0.028
0
0
0

med
0.985
0
0
0
neutral
0.985
0
0
0
neutral
0.000
0
0
0

Major
0.010
0
0
0
Major
0.708
0
0
0
Major
0.000
0
0
0

high
0.000
0
0
0
likely
0.015
0
0
0
likely
0.000
0
0
0

initial
first
second
third
initial
first
second
third
initial
first
second
third

initial
unlikely
neutral
likely
initial
unlikely
neutral
likely
initial
unlikely
neutral
likely

